Ovarian endometrioid carcinoma with sex cord-like features: a case report with genomic and transcriptomic analyses and literature review
Frontiers in Oncology · 29.05.2026 · 16
DOI: 10.3389/fonc.2026.1826424 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 29.05.2026. Verfasst von Shanshan Guo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Shen Kang Hospital Development Center, National Natural Science Foundation of China, Shanghai University of Traditional Chinese Medicine.
Abstract (Originalsprache)
Endometrioid carcinoma resembling sex cord-stromal tumour (SCLEC) is a rare histologic variant of ovarian endometrioid carcinoma characterized by trabecular, nested, or retiform growth patterns resembling sex cord-stromal tumors, while preserving the immunophenotypic and molecular features of endometrioid differentiation. Accurate diagnosis requires careful histopathologic assessment and exclusion of true sex cord-stromal neoplasms. We report a 71-year-old woman who underwent comprehensive staging surgery and was diagnosed with left-sided low-grade ovarian endometrioid carcinoma with sex cord-like features (stage IA1). Hematoxylin and eosin (HE) staining and immunohistochemistry(IHC) demonstrated morphologic resemblance to sex cord tumors, particularly granulosa cell tumors, with positivity for epithelial markers and negativity for sex cord differentiation markers. Molecular subtyping and transcriptomic sequencing identified a p.D32Y missense mutation in exon 3 of CTNNB1. Transcriptomic profiling showed that the WNT pathway was the dominant oncogenic driver, whereas the Rap1 pathway was significantly enriched but transcriptionally repressed. These findings suggest that disruption of adherens junctions and cell-cell adhesion may contribute to loss of epithelial polarity and the development of sex cord-like morphology. The patient remains in remission with no evidence of disease. To our knowledge, this is the first reported case of ovarian SCLEC characterized by transcriptome-based molecular profiling.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departments of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Departments of Central Laboratory for Science and Technology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Science and Technology Research Department, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Departments of Pathology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Förderung
- Shanghai Shen Kang Hospital Development Center
- National Natural Science Foundation of China
- Shanghai University of Traditional Chinese Medicine
Zitieren
APA
Guo, S., Tang, Q., Zhang, J., Zhao, W., Chen, S., Xia, H., Zhang, C., & Zhang, X. (2026). Ovarian endometrioid carcinoma with sex cord-like features: a case report with genomic and transcriptomic analyses and literature review. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1826424
Vancouver
Guo S, Tang Q, Zhang J, Zhao W, Chen S, Xia H, et al. Ovarian endometrioid carcinoma with sex cord-like features: a case report with genomic and transcriptomic analyses and literature review. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1826424
BibTeX
@article{Guo2026,
author = {Guo, Shanshan and Tang, Qianjue and Zhang, Jie and Zhao, Wei and Chen, Siru and Xia, Hong and Zhang, Chunyan and Zhang, Xiaoyun},
title = {Ovarian endometrioid carcinoma with sex cord-like features: a case report with genomic and transcriptomic analyses and literature review},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1826424}
}
EUVIMED